c3 glomerulopathy: a clinical approach. · disease and other c3 glomerulopathies. a servais, vfb....
TRANSCRIPT
![Page 1: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/1.jpg)
C3 Glomerulopathy: A clinical approach.
Fadi Fakhouri
ITUN, Department of nephrology and Immunology,
CHU de Nantes.
INSERM UMR S-1064
![Page 2: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/2.jpg)
« Membranoproliferative » is a pathological feature
Mesangial expansion « Doubles contours »
Immune deposits
![Page 3: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/3.jpg)
MPGN I
MPGN : classification
![Page 4: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/4.jpg)
MPGN II/DDD
MPGN : classification
![Page 5: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/5.jpg)
MPGN II/DDD
MPGN : classification
![Page 6: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/6.jpg)
C9
C3
MPGN II/DDD
MPGN : classification
![Page 7: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/7.jpg)
MPGN III
MPGN : classification
![Page 8: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/8.jpg)
SLE HCV/Cryoglobulinemia
MPGN secondary to monoclonal gammapathy
Secondary MPGN
MPGN : classification
TMA Chronic infections
![Page 9: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/9.jpg)
Some MPGN do not have a « MPGN » pattern
Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Nasr S, CJASN 2009; 4: 22-32.
n=32 DDD cases
MPGN 44% Mesangial GN 28%
EndoC Proliferation 19% Crescentic GN 9%
![Page 10: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/10.jpg)
Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Nasr S, CJASN 2009; 4: 22-32.
n=27 DDD cases
Outcome of DDD patients n=27 Mean follow-up: 5 years Complete response to TRT CKD ESRD Death
Is it «DDD versus the rest of MPGN »?
26% 48% 25% 11%
![Page 11: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/11.jpg)
Acquired and genetic complement abnormalities play a critical role in dense deposit
disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64.
Do MPGN types differ?
![Page 12: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/12.jpg)
Do MPGN types differ?
Acquired and genetic complement abnormalities play a critical role in dense deposit
disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64.
![Page 13: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/13.jpg)
Do MPGN types differ?
Acquired and genetic complement abnormalities play a critical role in dense deposit
disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64.
![Page 14: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/14.jpg)
![Page 15: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/15.jpg)
Is it «DDD versus the rest of MPGN »?
Little MA, KI 2006.
Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk.
![Page 16: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/16.jpg)
AS, VFB KI 2012
Do MPGN types differ?
![Page 17: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/17.jpg)
AS, VFB KI 2012
Do MPGN types differ?
![Page 18: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/18.jpg)
Do MPGN types differ?
C3Nef
58% 53% 86% 45%
![Page 19: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/19.jpg)
Do MPGN types differ?
C3Nef
58% 53% 86% 45%
![Page 20: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/20.jpg)
Isolated C3 deposits glomerulonephritis:
a new entity.
![Page 21: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/21.jpg)
MPGN I
DDD
C3GN
IF C3 deposits Ig deposits
+ +
+ -
+ -
EM Dense deposits
-
+
-
Reclassifying MPGN: a mission impossible?
![Page 22: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/22.jpg)
MPGN I
DDD
C3GN
IF C3 deposits Ig deposits
+ +
+ -
+ -
EM Dense deposits
-
+
-
Reclassifying MPGN: a mission impossible?
![Page 23: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/23.jpg)
2010
![Page 24: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/24.jpg)
Noris, NEJM, 2010
Is C3 the culprit in MPGN?
![Page 25: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/25.jpg)
Complement-dysregulation associated nephropathies
![Page 26: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/26.jpg)
Complement-dysregulation associated nephropathies
aHUS
C3 Glomerulopathy
F Fakhouri Nature Rev Nephrology, 2010
![Page 27: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/27.jpg)
Complement-dysregulation associated nephropathies
aHUS
C3 Glomerulopathy
DDD
C3G
F Fakhouri Nature Rev Nephrology, 2010
![Page 28: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/28.jpg)
MPGN I
DDD
C3GN IF
C3 deposits
+
+
+
Reclassifying MPGN: a mission impossible?
![Page 29: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/29.jpg)
![Page 30: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/30.jpg)
![Page 31: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/31.jpg)
![Page 32: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/32.jpg)
![Page 33: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/33.jpg)
Complement-dysregulation associated nephropathies
aHUS
C3 Glomerulopathy
DDD
C3G
MPGN pattern
F Fakhouri Nature Rev Nephrology, 2010
![Page 34: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/34.jpg)
Complement-dysregulation associated nephropathies
aHUS
C3 Glomerulopathy
DDD
C3G
MPGN pattern
Primary
MPGN I
Secondary
MPGN
F Fakhouri Nature Rev Nephrology, 2010
![Page 35: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/35.jpg)
10/23 patients had different IF patterns on repeat kidney biopsy
![Page 36: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/36.jpg)
u C 3 c o n v e r t a s e
C 5 c o n v e r t a s e
s M A C
i C 3 b
C 3
C 5 b
C 5
C 6 , 7 , 8 , 9
C 3 b
Complement system
Anti C3/C3b Ab
Eculizumab
FH FH/CR1
Anti-MASP Ab
rhC1INH
![Page 37: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/37.jpg)
Eculizumab
![Page 38: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/38.jpg)
![Page 39: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/39.jpg)
6/10 improved
![Page 40: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/40.jpg)
![Page 41: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/41.jpg)
C3c C3d C3c C3d
C5b9 C5b9
Eculizumab for rapidly progressing C3G: case 1
![Page 42: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/42.jpg)
C3c C3d C3c C3d
C5b9 C5b9
Eculizumab for rapidly progressing C3G: case 1
C. Kandel et K. Renaudin
![Page 43: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/43.jpg)
C3c C3d C3c C3d
C5b9 C5b9
Eculizumab for rapidly progressing C3G: case 1
C. Kandel et K. Renaudin
![Page 44: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/44.jpg)
C3c C3d C3c C3d
C5b9 C5b9
Eculizumab for rapidly progressing C3G: case 1
C. Kandel et K. Renaudin
C3d
![Page 45: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/45.jpg)
A personal view of the management of C3G/MPGN
![Page 46: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/46.jpg)
A personal view of the management of C3G/MPGN
Complement tests 1
C3Nef
C3, FB, sC5b-9 (urinary?), C5b-9 staining in KB
Anti-FH Ab, Monoclonal gammapathy
![Page 47: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/47.jpg)
Sheep erythrocyte lysis assay.
J Immunol 2015
![Page 48: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/48.jpg)
CJASN 2011
N= 6
5 MGRS + 1 smouldering M (kappa 4/6)
Light chain Puria 5
Low C3 and/or FB: 4/6
Anti-FH IgG 1/6
No complement gnes variants 4/4
No C3 nef 6/6
ESRD 5/6 (chemotherapy 4)
![Page 49: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/49.jpg)
Study of Ig L chain restriction of anti-FH recognition by ELISA. The binding of anti-FH IgG was revealed using an anti-κ or anti-λ
human Ig L chain.
J Immunol 2015
![Page 50: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/50.jpg)
JI 1999
Conversion of C3 by alternative C3 convertase
Binding of LC to FH
![Page 51: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/51.jpg)
A personal view of the management of C3G/MPGN
Complement tests 1
C3Nef: pathogenic relevance?
C3, FB, sC5b-9 (urinary?), C5b-9 staining in KB
Anti-FH Ab, Monoclonal gammapathy
KB 2 Cellular proliferation
Inflammatory cells infiltration
Fibrosis
EM
![Page 52: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/52.jpg)
A personal view of the management of C3G/MPGN
Complement tests 1
C3Nef: pathogenic relevance?
C3, FB, sC5b-9 (urinary?), C5b-9 staining in KB
Anti-FH Ab, Monoclonal gammapathy
KB 2 Cellular proliferation
Inflammatory cells infiltration
Fibrosis
EM
Not all C3G/MPGN are to be (agressively) treated 3
![Page 53: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/53.jpg)
A personal view of the management of C3G/MPGN
Complement tests 1
C3Nef: pathogenic relevance?
C3, FB, sC5b-9 (urinary?), C5b-9 staining in KB
Anti-FH Ab, Monoclonal gammapathy
KB 2 Cellular proliferation
Inflammatory cells infiltration
Fibrosis
EM
Not all C3G/MPGN are to be (agressively) treated 3
1st-line treatment: Cs + MMF
FFP/PE: FH deficiency 4
![Page 54: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/54.jpg)
KI, 2015
![Page 55: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/55.jpg)
KI, 2015
![Page 56: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/56.jpg)
KI, 2015
3pts/60 (5%) had complement genes variants: two pathogenic variants (cfh, c3) and at-risk mcp polymorphism.
![Page 57: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/57.jpg)
KI, 2015
![Page 58: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/58.jpg)
KI, 2015
![Page 59: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/59.jpg)
KI, 2015
![Page 60: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/60.jpg)
A personal view of the management of C3G/MPGN
Complement tests 1
C3Nef: pathogenic relevance?
C3, FB, sC5b-9 (urinary?), C5b-9 staining in KB
Anti-FH Ab, Monoclonal gammapathy
KB 2 Cellular proliferation
Inflammatory cells infiltration
Fibrosis
EM
Not all C3G/MPGN are to be (agressively) treated 3
1st-line treatment: Cs + MMF
FFP/PE: FH deficiency 4
2nd-line treatment: Eculizumab 5 RPGN
Elevated sC5b-9
Inflammatory changes in KB
![Page 61: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/61.jpg)
C3G: two parts of the disease.
![Page 62: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/62.jpg)
Anti C3/C3b Ab
Eculizumab
FH FH/CR1 sCR1
![Page 63: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/63.jpg)
Three concepts
1. « MPGN » is a pathological feature
« C3GN » relates to pathogenesis
2. Treatment of C3G should target AP dysregulation.
3. Eculzimab (and cie) are potential therapies
![Page 64: C3 Glomerulopathy: A clinical approach. · disease and other C3 glomerulopathies. A Servais, VFB. KI 2012; 82: 454-64. Do MPGN types differ? Acquired and genetic complement abnormalities](https://reader034.vdocuments.net/reader034/viewer/2022050214/5f6017ef43c448271a6b3800/html5/thumbnails/64.jpg)